NDA 020694 · Janssen Pharma
Sporanox
Itraconazole · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Dec 6, 1996 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Dec 6, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
507
27 Phase 3, 40 recruiting
FAERS reports
11,784
10,489 serious, 2,277 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 6, 1996 Original approval · Type 6 - New Indication (no longer used) Review
1 products under this application
- SPORANOX · ITRACONAZOLE 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Itraconazole" as an intervention, any sponsor and status, largest first.
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.Pivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00356915 · 1,381 participants · Start Jul 2006 · Primary completion Oct 2008
Drug: Itraconazole 100mg capsules; Itraconazole 200mg tablets and 1 more · For: Onychomycosis
Sites: Birmingham, Alabama; Tuscon, Arizona; Hot Springs, Arkansas · 68 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Recruiting
GenmabIndustry
NCT05579366 · 952 participants (planned) · Start Dec 7, 2022 · Primary completion Dec 2028
Drug: Rina-S; Carboplatin and 4 more · For: High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma and 13 more
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 67 sites in all
DualityBio Inc.Industry
NCT05914116 · 862 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 2027
Drug: DB-1311; Lopinavir and Ritonavir Tablets and 3 more · For: Advanced Solid Tumors
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 107 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
DualityBio Inc.Industry
NCT05150691 · 796 participants (planned) · Start Jan 31, 2022 · Primary completion Aug 2027
Drug: DB-1303/BNT323; Pertuzumab Injection and 2 more · For: HER2-positive Advanced Solid Tumor
Sites: Cerritos, California; Los Angeles, California; San Diego, California · 102 sites in all
- Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT03907046 · 700 participants (planned) · Start Jan 28, 2020 · Primary completion Apr 2027
Drug: Apixaban; Aspirin · For: Intracerebral Hemorrhage; Atrial Fibrillation
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 187 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction1,191
- drug ineffective1,144
- off label use632
- pyrexia589
- dyspnoea493
- pneumonia484
- nausea468
- diarrhoea404
- condition aggravated400
- febrile neutropenia373
- fatigue351
- rash310
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 277 |
| 2005 | 192 |
| 2006 | 219 |
| 2007 | 254 |
| 2008 | 291 |
| 2009 | 408 |
| 2010 | 361 |
| 2011 | 621 |
| 2012 | 587 |
| 2013 | 409 |
| 2014 | 373 |
| 2015 | 610 |
| 2016 | 474 |
| 2017 | 517 |
| 2018 | 703 |
| 2019 | 826 |
| 2020 | 868 |
| 2021 | 782 |
| 2022 | 676 |
| 2023 | 676 |
| 2024 | 601 |
| 2025 | 566 |
| 2026 | 492 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sporanox (Itraconazole)
2024 spending
$123K
Beneficiaries
26
82 claims
Per beneficiary
$4,730
$12.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $509,944 |
| 2021 | $247,250 |
| 2022 | $307,486 |
| 2023 | $196,502 |
| 2024 | $122,988 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.
Sehgal IS, Agarwal R, Dhooria S, et al. · Lancet Infect Dis 2026 · Randomized Controlled Trial, Comparative Study
- Coccidioidomycosis: clinical update.
Ampel NM, Wieden MA, Galgiani JN · Rev Infect Dis 1989 · Clinical Trial, Randomized Controlled Trial
- Itraconazole increases serum digoxin concentration.
Partanen J, Jalava KM, Neuvonen PJ · Pharmacol Toxicol 1996 · Clinical Trial, Randomized Controlled Trial
- Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
Marks DI, Pagliuca A, Kibbler CC, et al. · Br J Haematol 2011 · Multicenter Study, Randomized Controlled Trial
- Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Gibbons JA, de Vries M, Krauwinkel W, et al. · Clin Pharmacokinet 2015 · Clinical Trial, Phase I, Clinical Trial, Phase III
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.